Steven Seedhouse's Stock Ratings

Raymond James Analyst

Steven Seedhouse is an analyst at Raymond James. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/01/2024

Overall Average Return

3.74%

Smart Score

57.9%

Overall Average Return Percentile

46th

Number of Ratings

127
Buy NowGet Alert
05/16/2024VKTXBuy Now
Viking Therapeutics
$62.4685.72%$115 → $116UpgradeOutperform → Strong BuyGet Alert
05/10/2024VERABuy Now
Vera Therapeutics
$37.9978.99%$57 → $68MaintainsStrong BuyGet Alert
04/18/2024DNTHBuy Now
Dianthus Therapeutics
$21.61136%$34 → $51MaintainsOutperformGet Alert
03/12/2024NGMBuy Now
NGM Biopharmaceuticals
———DowngradeOutperform → Market PerformGet Alert
02/27/2024VKTXBuy Now
Viking Therapeutics
$62.4684.12%$37 → $115MaintainsOutperformGet Alert
02/13/2024CBAYBuy Now
CymaBay Therapeutics
——$32.5 → $32.5DowngradeStrong Buy → Market PerformGet Alert
01/26/2024VERABuy Now
Vera Therapeutics
$37.99-2.61%$29 → $37UpgradeOutperform → Strong BuyGet Alert
01/11/2024APLSBuy Now
Apellis Pharmaceuticals
$39.32169.58%$67 → $106MaintainsStrong BuyGet Alert
01/09/2024ARDXBuy Now
Ardelyx
$6.86118.66%$12 → $15MaintainsStrong BuyGet Alert
01/04/2024DYNBuy Now
Dyne Therapeutics
$31.8875.66%$27 → $56MaintainsStrong BuyGet Alert
12/19/2023MIRMBuy Now
Mirum Pharmaceuticals
$24.03166.33%$78 → $64MaintainsStrong BuyGet Alert
12/18/2023VERABuy Now
Vera Therapeutics
$37.99-23.66% → $29Initiates → OutperformGet Alert
12/18/2023ARDXBuy Now
Ardelyx
$6.8674.93% → $12Initiates → Strong BuyGet Alert
12/15/2023APLSBuy Now
Apellis Pharmaceuticals
$39.3270.4%$93 → $67MaintainsStrong BuyGet Alert
11/14/2023LPTXBuy Now
Leap Therapeutics
$2.43620.16%$18.5 → $17.5MaintainsOutperformGet Alert
11/10/2023NTLABuy Now
Intellia Therapeutics
$23.10146.75%$78 → $57MaintainsOutperformGet Alert
11/08/2023CBAYBuy Now
CymaBay Therapeutics
——$33 → $34MaintainsStrong BuyGet Alert
11/08/2023PRQRBuy Now
ProQR Therapeutics
$1.95105.13%$5 → $4MaintainsOutperformGet Alert
11/02/2023IFRXBuy Now
InflaRx
$1.491175.17%$21 → $19MaintainsStrong BuyGet Alert
11/02/2023APLSBuy Now
Apellis Pharmaceuticals
$39.32136.52%$92 → $93MaintainsStrong BuyGet Alert
10/18/2023MIRMBuy Now
Mirum Pharmaceuticals
$24.03220.43%$84 → $77MaintainsStrong BuyGet Alert
10/06/2023APLSBuy Now
Apellis Pharmaceuticals
$39.32133.98%$89 → $92MaintainsStrong BuyGet Alert
09/28/2023DNTHBuy Now
Dianthus Therapeutics
$21.6111.06% → $24Initiates → OutperformGet Alert
09/08/2023CBAYBuy Now
CymaBay Therapeutics
——$17 → $33MaintainsStrong BuyGet Alert
09/07/2023CBAYBuy Now
CymaBay Therapeutics
——$17 → $33MaintainsStrong BuyGet Alert
08/21/2023MIRMBuy Now
Mirum Pharmaceuticals
$24.03249.56%$79 → $84MaintainsStrong BuyGet Alert
08/15/2023ZURABuy Now
Zura Bio
$5.34311.99%$20 → $22MaintainsStrong BuyGet Alert
08/04/2023MIRMBuy Now
Mirum Pharmaceuticals
$24.03228.76%$82 → $79MaintainsStrong BuyGet Alert
08/01/2023APLSBuy Now
Apellis Pharmaceuticals
$39.32126.35%$156 → $89MaintainsStrong BuyGet Alert
07/18/2023MIRMBuy Now
Mirum Pharmaceuticals
$24.03241.24%$81 → $82MaintainsStrong BuyGet Alert

Recent Analyst Stock Rating News

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
A Closer Look at 6 Analyst Recommendations For Ardelyx
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
Critical Insights From Mirum Pharmaceuticals Analyst Ratings: What You Need To Know
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
Where Ardelyx Stands With Analysts
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Analyst Highlights 'Rock Solid' Data For Vera Therapeutics' Kidney Disease-Targeted Atacicept, Upgrades To Strong Buy
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.
What's Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free